FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Study Questions Safety of Reprocessed Blades

[ Price : $8.95]

Loma Linda University researchers say they found contamination and damage in many reprocessed single-use arthroscopic shaver blade...

FDA Asked to Warn Against Epilepsy Drug Switches

[ Price : $8.95]

UCB asks FDA to tell physicians and pharmacists to be cautious when switching patients anti-epileptic medications, including switc...

Novartis Zaditor Going OTC

[ Price : $8.95]

FDA approves OTC status for Novartis Zaditor, indicated for preventing itchy eyes due to allergic conjunctivitis.

Neurological Devices Panel Meeting Postponed

[ Price : $8.95]

Federal Register Notice: FDA postpones a 10/31 Neurological Devices Panel to further evaluate data.

Lilly to Challenge FDA Request for Study on NDA

[ Price : $8.95]

Eli Lilly says it will appeal CDERs decision to issue an approvable letter that requests an additional efficacy study for its NDA ...

FDA Extends Use of Older MedWatch Form

[ Price : $8.95]

FDA extends the use of an older version of its MedWatch 3500A form to allow industry time to modify their computer systems.

FDA Generic Drug Submissions Increase

[ Price : $8.95]

CDER Office of Generic Drugs director Gary Buehler reports a slight increase in workload last year added to stress felt in his ove...

FDA OKs Stronger Reyataz Dosage Strength

[ Price : $8.95]

FDA approves a 300 mg capsule formulation of Bristol-Myers Squibbs Reyataz to be used in combination therapy along with ritonavir ...

Panel to Discuss Celebrex for Junior RA

[ Price : $8.95]

Federal Register Notice: FDAs Arthritis Advisory Committee will meet 11/29 to discuss Pfizers Celebrex for the proposed indication...

Lilly Planning Cialis Ad Push?

[ Price : $8.95]

Advertising Age reports Lilly may be planning an advertising push for Cialis.